Home > Insider Trading > Filing (0001127602-10-007294)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
729922	Osi Pharmaceuticals Inc	OSIP	In Vitro & In Vivo Diagnostic Substances (2835)	133159796

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1220051	A Barbara Wood	C/O Osi Pharmaceuticals, Inc. 41 Pinelawn Road Melville NY 11747	Sr. V.p. & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-03-01	20,000	$35.88	47,366	No	4	M	Direct
Common Stock	Disposition	2010-03-01	20,000	$55.11	27,366	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2010-03-01	20,000	$0.00	20,000	$35.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,000	2002-04-02	2011-04-01	No	4	M	Direct

Footnotes

Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2008. Transaction occured upon the exercise of options due to expire on April 1, 2011.
The price reported represents the weightedaverage sales price of shares sold in multiple transactions at prices ranging from $55.11 to $55.15 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
One third of the stock option became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months.
Includes only options with the same termination date.